Long-term follow-up of mesh-covered stent implantation in patients with ST-segment elevation myocardial infarction by Dudek, Dariusz et al.
www.kardiologiapolska.pl
Kardiologia Polska 2014; 72, 2: 140–145; DOI: 10.5603/KP.a2013.0252 ISSN 0022–9032
ARTYKUŁ ORYGINALNY / ORIGINAL ARTICLE
Long-term follow-up of mesh-covered stent  
implantation in patients with ST-segment  
elevation myocardial infarction
Dariusz Dudek1, Artur Dziewierz1, Paweł Kleczyński1, Dawid Giszterowicz2, Tomasz Rakowski1,  
Danuta Sorysz1, Łukasz Rzeszutko1, Jacek Legutko1, Stanisław Bartuś1, Jacek Dragan2, Artur Klecha3,  
Zbigniew Siudak1, Krzysztof Żmudka1
1Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland
2Department of Interventional Cardiology, Nowy Sacz, Poland
3Department of Interventional Cardiology, Nowy Targ, Poland
A b s t r a c t
Background: The MGuard stent (a bare-metal stent wrapped externally in a polymer mesh sleeve) was introduced to reduce 
the risk of distal embolisation and no-reflow phenomenon during percutaneous coronary intervention (PCI) in thrombus con-
taining lesions, including ST-segment elevation myocardial infarction (STEMI). However, data on the long-term performance 
of the MGuard stent is limited.
Aim: To assess the long-term safety and efficacy of MGuard stent implantation during primary PCI for STEMI.
Methods and results: In this multicentre study, a total of 60 patients with STEMI £ 12 h treated with the MGuard stent were 
enrolled. Angiographic success of PCI was achieved in 96.7%, with the final TIMI grade 3 flow in 90.0% of patients. At six 
months, the overall rate of major adverse cardiac and cerebrovascular events (MACCE; composite of cardiac death, nonfatal 
target vessel reinfarction, target lesion revascularisation, and stroke) was 1.7%. A long-term follow-up of the study was suc-
cessfully performed in 57 patients (mean follow-up of 38.7 ± 3.1 months). The long-term cardiac mortality was 7.0%, with 
a MACCE rate of 8.8%. There was no decrease in the left ventricular ejection fraction and no enlargement of the left ventricle 
between index and long-term follow-up echocardiogram.
Conclusions: The early safety and efficacy of the MGuard stent was maintained during the long-term follow-up. However, 
comparative data from ongoing randomised clinical trials are still required to confirm the long-term efficacy of MGuard stent 
implantation in patients with STEMI.
Key words: primary angioplasty, acute myocardial infarction, stent, mesh, long-term outcomes
Kardiol Pol 2014; 72, 2: 140–145
Address for correspondence:  
Dariusz Dudek, MD, PhD, FESC, Department of Interventional Cardiology, Jagiellonian University Medical College, ul. Kopernika 17, 31–501 Kraków, Poland,  
tel: +48 12 424 71 81, fax: +48 12 424 71 84, e-mail: mcdudek@cyfronet.pl 
Received: 02.05.2013 Accepted: 03.09.2013 Available as AoP: 12.09.2013
Copyright © Polskie Towarzystwo Kardiologiczne
INTRODUCTION
The mesh-covered stent (MGuardTM Coronary Stent System, 
InspireMD Ltd., Israel) is a bare-metal stent covered with 
an ultra thin, micron level, flexible mesh sleeve [1, 2]. It 
was introduced to reduce the risk of distal embolisation 
and no-reflow phenomenon during percutaneous coronary 
intervention (PCI) in the thrombus containing lesions, i.e. 
ST-segment elevation myocardial infarction (STEMI) setting 
and degenerated saphenous vein grafts [1, 3–5]. The feasi-
bility and short-term efficacy of MGuard stent implantation 
during primary PCI for STEMI has been confirmed by prev-
ious studies [2, 4, 5], including the MGuardTM Coronary Stent 
System in ST-Elevation Myocardial Infarction — A European 
Post-Market Clinical Study (MAGICAL) [4]. Recently, the 
Safety and Efficacy Study of MGuard Stent After a Heart At-
tack (MASTER) Trial [6] has shown that among patients with 
STEMI, the mesh-covered stent compared to conventional 
metal stents resulted in superior rates of epicardial coronary 
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flow and complete ST-segment resolution during and after 
primary PCI. However, limited information is still available 
as to the long-term efficacy of the MGuard stent.
The purpose of the extended follow-up of the MAGICAL 
study was to assess the long-term clinical outcomes of patients 
treated with the MGuard stent during primary PCI for STEMI.
METHODS
Detailed descriptions of the MAGICAL study protocol and 
main results have been published previously [4]. Briefly, 
60 patients with STEMI £ 12 h were enrolled in four centres in 
Poland from July 2008 to May 2009. The main clinical exclu-
sion criteria were: contraindications to antiplatelet and/or an-
tithrombotic treatment, known history of chronic renal disease 
or haemodialysis, cardiopulmonary resuscitation, cardiogenic 
shock, and left ventricular ejection fraction (LVEF) < 30%. 
The main angiographic exclusion criteria were: presence 
of excessive vessel tortuosity, diffuse disease or severe le-
sion/vessel calcification, left main stenosis > 60%, saphenous 
vein graft stenosis, in-stent thrombosis, and bifurcation lesion 
with side-branch > 1.5 mm. The use of atherectomy and/or 
thrombectomy catheters or/and embolic protection devices 
was not permitted before stent implantation. After enrollment 
of 30 patients, the protocol of the study was changed and the 
use of simple aspiration catheters before stenting was at the 
discretion of the operator.
Treatment strategy 
In all patients, a loading dose of acetylsalicylic acid (ASA) and 
clopidogrel (600 mg PO) was given. The choice of antithrom-
bin (unfractionated heparin or bivalirudin) and glycoprotein 
(GP) IIb/IIIa inhibitor was at the discretion of the operator. 
In all patients, primary PCI with MGuard stent implantation 
was performed. Direct implantation of the MGuard stent 
followed by post-dilatation was allowed only if there was 
adequate visualisation of the distal vessel following wiring 
of the vessel. If the distal coronary vessel was not visualised 
with wiring, predilatation with a £ 2.0 mm balloon using low 
pressures was recommended. The use of simple aspiration 
catheters was permitted only in the last 30 patients. Dual 
antiplatelet therapy was recommended for 12 months (ASA 
75 mg PO daily, clopidogrel 75 mg PO daily). Adjunctive 
drugs were used in compliance with the current guidelines 
for STEMI management.
Clinical assessment
The primary angiographic and electrocardiographic outcomes 
have been published previously [4]. In the MAGICAL study, 
patients were followed for six months for cardiovascular 
events, all-cause and cardiac death, reinfarction, stent throm-
bosis, repeat target lesion revascularisation (TLR) and target 
vessel revascularisation (TVR), and stroke. Following the 
original protocol conclusion, an extended follow-up of the 
MAGICAL study was approved by the Jagiellonian University 
bioethics committee in Krakow, Poland and conducted. In 
April 2012, patients were contacted again and data on car-
diovascular events occurrence beyond the original six-month 
follow-up was collected. Follow-up information was obtained 
by telephone interview with surviving patients, or family 
members using a structured questionnaire. If possible, patients 
were asked to come for an office visit and echocardiogram. 
In the case of event, medical records and angiograms were 
collected from patients or the relevant medical centres. Major 
adverse cardiac and cerebrovascular events (MACCE) were 
defined as a composite of cardiac death, nonfatal target vessel 
reinfarction, TLR, and stroke. Major adverse cardiac events 
(MACE) were defined as composite of cardiac death, nonfatal 
target vessel reinfarction, and TLR. Events were reported in 
hierarchical order. Stent thrombosis was defined according 
to the Academic Research Consortium criteria [7]. All clinical 
events were adjudicated by an independent clinical events 
committee using original source documents. Data quality and 
completeness were monitored.
Statistical analysis
Results were presented as numbers of patients (percentages) 
or mean ± standard deviation where applicable. Cumula-
tive cardiac mortality and MACCE rates during follow-up 
were calculated with the Kaplan-Meier method. Differences 
in the LVEF and left ventricular end-diastolic dimension be-
tween index and follow-up echocardiogram were analysed 
with a paired sample t-test. All tests were two-tailed, and 
a p value < 0.05 was considered statistically significant. All 
statistical analysis was performed using SPSS 15.0 (SPSS, Inc., 
Chicago, IL, USA).
RESULTS
Sixty patients were enrolled into the study. The main results 
of the study, including the primary angiographic and elec-
trocardiographic outcomes, have been published previously 
[4]. Baseline characteristics and invasive treatment details are 
shown in Table 1. All patients were pretreated with a clopidogrel 
loading dose of 600 mg, and 59 (98.3%) patients received 
an ASA loading dose of 325 mg before angiography. In most 
patients (65.0%), the right coronary artery was identified as the 
infarct-related artery (Table 1). Patent infarct-related artery at 
baseline — Thrombolysis In Myocardial Infarction (TIMI) grade 
2 or 3 flow was found in 22 (36.6%) patients. In all patients, 
a weight-adjusted dose of unfractionated heparin was given. 
Additionally, in 24 (40.0%) patients a GP IIb/IIIa inhibitor (ab-
ciximab) was used during primary PCI. The mean time-delay 
from chest pain onset to stent implantation was 269 ± 155 min. 
The angiographic success of PCI was achieved in 58 (96.7%) 
with the final TIMI grade 3 flow in 54 (90.0%) patients. 
No ischaemic complications were observed during the 
index hospital stay. Clopidogrel and ASA were prescribed at 
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index procedure. The study stent was patent and without 
significant stenosis.
By protocol definition, six-month rates of MACCE and 
MACE were 1.7% and 0%, respectively. A long-term follow-up 
of the MAGICAL study was successfully performed in 57 (95%) 
patients. Three (5%) patients were lost to follow-up. The mean 
follow-up was 38.7 ± 3.1 months (range 34.2–44.3 months). 
Beyond the six months, there was one (1.8%) TVR and 
one (1.8%) TLR, without nonfatal target vessel reinfarction. 
Additionally, there was one (1.8%) non-cardiac death and 
four (7.0%) cardiac deaths. However, one of the cardiac 
deaths occurred in a patient with a previous stroke event, 
and a second in a patient undergoing TVR. Total three-year 
cardiac mortality was low — 7.0%. There was no definite 
or probable stent thrombosis (according to the Academic 
Research Consortium criteria). Finally, there were five (8.8%) 
MACE and five (8.8%) MACCE. Kaplan-Meier curves for 
cardiac death and MACCE are shown in Figure 1. Long-term 
echocardiography was performed in 32 patients. There was 
no significant decrease in the LVEF (index vs. follow-up 
examination: 55.1 ± 11.5% vs. 57.3 ± 8.6%; p = 0.17) 
and no enlargement of the left ventricle (the left ventricular 
end-diastolic dimension: 5.1 ± 0.4 cm vs. 5.2 ± 0.5 cm; 
p = 0.22) between index and follow-up echocardiogram. 
No differences in baseline characteristics and angiographic 
parameters were observed between patients with and without 
follow-up echocardiography.
DISCUSSION
In this prospective series of patients with STEMI, the early 
safety and efficacy of MGuard stent implantation was main-
tained during the long-term follow-up and the observed 
MACCE rate was low — 8.8%.
discharge in all patients. During six-month follow-up, there 
was one (1.7%) TVR and one (1.7%) ischaemic stroke. In 
the patient who needed TVR, an additional stent was im-
planted in the segment other than that treated during the 
Table 1. Baseline demographics and invasive treatment details
Variable N = 60
Males 44 (73.0%)
Age [years] 61.6 ± 9.6
Arterial hypertension 32 (53.3%)
Hyperlipidaemia 31 (51.7%)
Diabetes mellitus 5 (8.3%)
Previous MI 3 (5.0%)
Previous PCI 2 (3.3%)
Previous CABG 0 (0.0%)
Current smoker 33 (55.0%)
Heart rate on admission [bpm] 76.9 ± 14.2
Systolic BP on admission [mm Hg] 143.9 ± 24.6
Diastolic BP on admission [mm Hg] 76.9 ± 14.2
Infarct related artery:
Left anterior descending artery 17 (28.3%)
Circumflex artery 4 (6.7%)
Right coronary artery 39 (65.0%)
Thrombus presence 51 (85.0%)
Aspiration catheter used 11 (18.3%)
Predilatation performed 37 (61.7%)
Postdilatation performed 32 (53.3%)
BP — blood pressure; CABG — coronary artery bypass grafting;  
MI — myocardial infarction; PCI — percutaneous coronary intervention
Figure 1. Kaplan-Meier curves for cardiac deaths (A) and major adverse cardiac and cerebrovascular events (B)
A B
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of 0.372 ± 0.23 mm and a mean per cent diameter stenosis 
of 30.6% at control angiogram performed six months after 
stent implantation [3]. Despite the lack of an antiprolifera-
tive agent, the rate of TLR for the MGuard stent during the 
three-year follow-up in our study was very low (1.7%). The risk 
of ischaemic TVR in patients after STEMI is potentially lower 
than in patients without infarction, as the infracted territory 
may be clinically silent when restenosis occurs. So, we can 
assume a slightly greater rate of TLR or TVR when a routine 
control angiogram is carried out [16]. Similarly, Piscione at al. 
[5] reported rates of 3.4% and 1.1% for TVR and definite stent 
thrombosis at two years, respectively. In the MASTER study, 
there was an increased risk of TLR (MGuard vs. control: 4.8% 
vs. 1.0%; p = 0.02) and TVR (6.2% vs. 1.0%; p < 0.01) at six 
months in patients treated with the MGuard stent compared 
to the available bare-metal stents or drug-eluting stents. How-
ever, the observed rate of restenosis was comparable to that 
reported for bare-metal stents in previous studies [12].
One-year results of the MASTER study will provide ad-
ditional data on the long-term performance of the MGuard 
stent. A second study, the MGuard vs. bare-metal stents 
plus manual thrombectomy in STEMI patients (GUARDIAN, 
NCT01124942), is going to compare the MGuard stent alone 
vs. thrombus aspiration with bare-metal stent implantation 
[17]. The results of these studies may allow assessment of 
the competing benefits (improved myocardial reperfusion) 
and risks (potentially higher risk of restenosis compared to 
drug-eluting stents) of the MGuard stent compared to con-
ventional metal stents.
Limitations of the study
The main limitation of the present study is a small sample 
and non-randomised study design. The study population was 
preselected based on inclusion and exclusion criteria, and thus 
may be a lower risk group. In addition, three (5%) patients 
were lost to follow-up, and the control echocardiogram was 
performed only in 32 patients. No routine control angiogram 
was performed. On the other hand, this is the second, large 
cohort of patients with STEMI treated with MGuard stent 
implantation during primary PCI with long-term clinical out-
come data available. 
CONCLUSIONS
The early safety and efficacy of the MGuard stent was main-
tained during the long-term follow-up. However, comparative 
data from ongoing randomised clinical trials is still required to 
confirm the long-term efficacy of MGuard stent implantation 
in patients with STEMI.
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The MGuard stent is designed to decrease the risk of distal 
embolisation during primary PCI for STEMI. In the MASTER 
study, its use compared to standard metal stents (bare-metal 
stent or drug-eluting stent) implantation in patients undergo-
ing primary PCI resulted in significantly higher rates of TIMI 
grade 3 flow, and complete ST-segment resolution after the 
procedure [6]. Importantly, the benefits in terms of improved 
ST-segment resolution related to MGuard stent use were 
observed in both patients with and without prior aspiration 
thrombectomy before stent implantation. As reported previ-
ously by our group [4], the rates of TIMI grade 3, myocardial 
blush grade 3, and complete ST-segment resolution after 
PCI were comparable to those observed in the MASTER trial 
(MAGICAL vs. MASTER: TIMI grade 3 — 90.0% vs. 91.8%; 
myocardial blush grade 3 — 73.3% vs. 74.2%; ST-segment 
resolution ≥ 70% — 61.4% vs. 57.8%) [6].
The achievement of early and sustained reperfusion not 
only on epicardial, but primarily on microcirculatory, level 
may lead to improved long-term survival, as the optimal 
myocardial perfusion is associated with improved patient 
outcomes [8–10]. In the MASTER trial, mortality at 30 days was 
greater in patients not achieving complete ST-segment reso-
lution after PCI, resulting in a strong trend towards reduced 
cardiac mortality in patients in whom the MGuard stent was 
implanted compared to a control stent [6]. This benefit was 
maintained during a six-month follow-up (MGuard vs control: 
0.5% vs. 2.8%; p = 0.056). As in our study, no deaths during 
a 30-day follow-up in patients treated with the MGuard stent 
were noted. Similar favourable clinical outcomes of patients 
with STEMI treated with the MGuard stent were reported by 
Piscione et al. [5]. 
However, data on the long-term performance of the 
MGuard stent is rather limited. In a group of 41 patients 
treated with the MGuard stent during PCI in old degener-
ated venous grafts and/or native coronaries culprit lesions in 
patients experiencing acute coronary syndromes, the total 
MACE rate at a mean follow-up of 20 months was 24.4%, 
with an all-cause mortality rate of 2.4% [11]. Data presented 
by Piscione et al. [5] during the TCT 2010 meeting for 
89 non-shock patients with STEMI revealed all-cause and 
cardiac mortality rates for two-year follow-up of 9.0% and 
2.2%, respectively. Our MACE and MACCE rates were slightly 
lower than those reported in the Harmonizing Outcomes with 
Revascularisation and Stents in Acute Myocardial Infarction 
(HORIZONS-AMI) trial for three-year follow-up, although with 
greater rates of all-cause and cardiac death [12]. In contrast, 
the long-term event rates were lower than those reported 
in large multicentre registries for patients treated with stent 
during primary PCI for STEMI [13–15].
The extent of restenosis within the MGuard stent can-
not be assessed, as a control angiography was not routinely 
performed in our study. In the first-in-man study, the rate of 
TVR for the MGuard stent was 11.1%, with a mean late loss 
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Obserwacja odległa implantacji stentu  
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Dariusz Dudek1, Artur Dziewierz1, Paweł Kleczyński1, Dawid Giszterowicz2, Tomasz Rakowski1,  
Danuta Sorysz1, Łukasz Rzeszutko1, Jacek Legutko1, Stanisław Bartuś1, Jacek Dragan2, Artur Klecha3,  
Zbigniew Siudak1, Krzysztof Żmudka1
1II Klinika Kardiologii, Instytut Kardiologii, Uniwersytet Jagielloński, Collegium Medicum, Kraków
2Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii, Nowy Sącz
3Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii, Nowy Targ
S t r e s z c z e n i e
Wstęp: Stent MGuard (stent stalowy pokryty z zewnątrz poliuretanową siateczką) został wprowadzony w celu redukcji ryzyka 
zatorowania obwodowego i zjawiska braku przepływu (no-reflow) w trakcie zabiegu angioplastyki wieńcowej (PCI) w zakresie 
zmiany zawierającej materiał zakrzepowy, w tym w zawale serca z uniesieniem odcinka ST (STEMI). Dane dotyczące wyników 
odległych implantacji stentu MGuard są jednak ograniczone.
Cel: Celem pracy była ocena odległego bezpieczeństwa i skuteczności implantacji stentu MGuard w trakcie zabiegu pier-
wotnej PCI w STEMI.
Metody i wyniki: Do tego wieloośrodkowego badania włączono łącznie 60 pacjentów ze STEMI i czasem trwania objawów 
poniżej 12 h, leczonych stentem MGuard. Sukces angiograficzny zabiegu osiągnięto u 96,7% osób, przy pełnym napływie 
obwodowym w zakresie tętnicy odpowiedzialnej za zawał (TIMI 3) stwierdzanym w 90% przypadków. W okresie 6-mie-
sięcznej obserwacji łączna częstość ciężkich zdarzeń sercowych i naczyniowo-mózgowych (MACCE; łącznie zgon z przyczyn 
sercowych, ponowny zawał niezakończony zgonem, ponowna rewaskularyzacja zmiany poddawanej angioplastyce i udar 
mózgu) wyniosła 1,7%. Obserwacja odległa badania została przeprowadzona u 57 pacjentów (średni okres obserwacji 
38,7 ± 3,1 miesiąca). Odległa śmiertelność z przyczyn sercowych wyniosła 7%, z częstością MACCE równą 8,8%. Nie zaob-
serwowano spadku wartości frakcji wyrzutowej lewej komory czy też powiększenia jamy serca między echokardiogramem 
wyjściowym a wykonanym w ramach obserwacji odległej.
Wnioski: Wczesne bezpieczeństwo i skuteczność stentu MGuard utrzymywało się w okresie obserwacji odległej. Nadal 
potrzebne są dane z trwających badań randomizowanych w celu potwierdzenia odległej skuteczności implantacji stentu 
MGuard u pacjentów ze STEMI.
Słowa kluczowe: pierwotna angioplastyka wieńcowa, zawał serca, stent, siateczka, rokowanie odległe
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